Adrian L Harris Selected Research

Carcinoma (Carcinomatosis)

11/2016	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.
7/2013	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
6/2011	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation.
7/2009	The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths.
1/2007	Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
6/2005	Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death.
4/2005	Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival.
12/2004	Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.
3/2003	GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
12/2002	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adrian L Harris Research Topics

Disease

247	Neoplasms (Cancer) 06/2022 - 01/2002
162	Hypoxia (Hypoxemia) 01/2022 - 01/2002
95	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2002
20	Neoplasm Metastasis (Metastasis) 02/2022 - 04/2002
13	Carcinogenesis 06/2015 - 01/2002
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2021 - 02/2003
12	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 05/2004
12	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 05/2002
12	Carcinoma (Carcinomatosis) 11/2016 - 04/2002
10	Melanoma (Melanoma, Malignant) 05/2013 - 05/2003
9	Urinary Bladder Neoplasms (Bladder Cancer) 08/2017 - 03/2002
9	Necrosis 07/2013 - 12/2002
8	Glioblastoma (Glioblastoma Multiforme) 06/2022 - 04/2003
8	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 12/2005
8	Adenocarcinoma 10/2015 - 07/2002
8	Head and Neck Neoplasms (Head and Neck Cancer) 04/2013 - 08/2002
6	Squamous Cell Carcinoma of Head and Neck 04/2013 - 05/2002
5	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 12/2002
5	Lung Neoplasms (Lung Cancer) 12/2018 - 06/2003
5	Anemia 11/2008 - 05/2004
5	Endometrial Neoplasms (Endometrial Cancer) 12/2006 - 04/2002
4	Kidney Neoplasms (Kidney Cancer) 09/2011 - 10/2005

Drug/Important Bio-Agent (IBA)

69	Proteins (Proteins, Gene)FDA Link 05/2021 - 08/2002
54	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2016 - 04/2002
39	Carbonic Anhydrase IXIBA 02/2022 - 08/2002
33	Oxygen (Dioxygen)IBA 02/2022 - 03/2002
30	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2003
29	EnzymesIBA 08/2021 - 02/2002
28	Transcription Factors (Transcription Factor)IBA 02/2016 - 02/2002
25	Messenger RNA (mRNA)IBA 01/2021 - 03/2002
22	Estrogen ReceptorsIBA 01/2020 - 05/2002
17	MicroRNAs (MicroRNA)IBA 12/2018 - 03/2008
16	LigandsIBA 01/2020 - 12/2004
15	Pharmaceutical PreparationsIBA 01/2022 - 08/2002
15	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 01/2002
13	Biological ProductsIBA 01/2020 - 07/2003
12	Bevacizumab (Avastin)FDA Link 08/2016 - 12/2007
11	Carbonic Anhydrases (Carbonic Anhydrase)IBA 01/2020 - 02/2003
10	Hypoxia-Inducible Factor 1IBA 12/2015 - 01/2004
9	AntibodiesIBA 02/2022 - 06/2006
9	Protein Isoforms (Isoforms)IBA 01/2022 - 09/2004
9	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 01/2005
9	Estrogens (Estrogen)FDA Link 01/2018 - 10/2003
8	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2002
8	Lactic Acid (Lactate)FDA LinkGeneric 12/2018 - 01/2005
8	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2017 - 03/2002
8	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 10/2016 - 07/2004
8	Tamoxifen FDA LinkGeneric 07/2014 - 04/2005
7	Hormones (Hormone)IBA 01/2019 - 08/2005
7	Letrozole (Femara)FDA LinkGeneric 05/2015 - 08/2006
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2015 - 12/2003
7	Thymidine PhosphorylaseIBA 06/2004 - 03/2002
6	GlycogenIBA 06/2022 - 12/2012
6	Estrogen Receptor alphaIBA 01/2018 - 05/2004
6	Oxidoreductases (Dehydrogenase)IBA 10/2016 - 06/2003
6	Monoclonal AntibodiesIBA 01/2016 - 01/2003
6	Aromatase InhibitorsIBA 05/2015 - 05/2008
6	Complementary DNA (cDNA)IBA 10/2013 - 10/2002
6	Lactate Dehydrogenase 5IBA 07/2011 - 01/2006
5	Bicarbonates (Hydrogen Carbonate)IBA 01/2022 - 10/2015
5	Glutamine (L-Glutamine)FDA Link 01/2021 - 01/2014
5	ChromatinIBA 12/2020 - 05/2010
5	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 10/2014
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 04/2010
5	LipidsIBA 01/2019 - 01/2013
5	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2019 - 01/2006
5	Phosphotransferases (Kinase)IBA 01/2019 - 09/2006
5	Small Interfering RNA (siRNA)IBA 12/2018 - 05/2010
5	Androgen Receptors (Androgen Receptor)IBA 01/2018 - 11/2005
5	Amifostine (Ethyol)FDA LinkGeneric 01/2018 - 01/2004
5	Epirubicin (Ellence)FDA LinkGeneric 10/2017 - 08/2006
5	LuciferasesIBA 01/2017 - 09/2006
5	AcidsIBA 03/2014 - 06/2007
5	Indicators and Reagents (Reagents)IBA 07/2013 - 10/2003
5	Angiogenesis InhibitorsIBA 06/2013 - 10/2002
5	CytokinesIBA 08/2010 - 10/2003
4	AntigensIBA 02/2022 - 01/2003
4	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 01/2019 - 01/2005
4	Histone DemethylasesIBA 01/2018 - 10/2009
4	Trastuzumab (Herceptin)FDA Link 03/2016 - 12/2010
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2012 - 05/2006
4	IronIBA 04/2010 - 12/2002
4	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 10/2008 - 05/2004
4	endothelial PAS domain-containing protein 1IBA 08/2007 - 03/2002
4	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 05/2006 - 03/2002
3	Polysaccharides (Glycans)IBA 02/2022 - 12/2016
3	EpitopesIBA 02/2022 - 01/2005
3	IsotopesIBA 04/2021 - 12/2018
3	Carbon DioxideIBA 01/2020 - 10/2015
3	Protons (Proton)IBA 01/2020 - 02/2004
3	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 05/2015
3	Mechanistic Target of Rapamycin Complex 1IBA 01/2020 - 11/2010
3	Amino Acids FDA Link 01/2019 - 01/2008
3	Phospholipids (Phosphatides)FDA LinkGeneric 12/2018 - 02/2002
3	Cadherins (E-Cadherin)IBA 01/2018 - 08/2011

Therapy/Procedure

110	Therapeutics 02/2022 - 03/2002
31	Radiotherapy 01/2022 - 01/2002
22	Drug Therapy (Chemotherapy) 01/2022 - 12/2002
6	Immunotherapy 10/2020 - 12/2003
4	Neoadjuvant Therapy 08/2016 - 08/2006